MX2021000312A - Composicion farmaceutica que contiene un peptido. - Google Patents

Composicion farmaceutica que contiene un peptido.

Info

Publication number
MX2021000312A
MX2021000312A MX2021000312A MX2021000312A MX2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A MX 2021000312 A MX2021000312 A MX 2021000312A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
peptide
composition containing
composition
linaclotide
Prior art date
Application number
MX2021000312A
Other languages
English (en)
Inventor
George Shlieout
Christopher Rupp
Ronny Schulze
Den Akker Rob Van
Kuldeep Bhokare
Jörn Lüders
Jörg Hagedorn
Original Assignee
Abbott Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories Gmbh filed Critical Abbott Laboratories Gmbh
Publication of MX2021000312A publication Critical patent/MX2021000312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Abstract

La presente invención se refiere a una composición farmacéutica estable para administración oral que comprende linaclotida o sales farmacéuticamente aceptables de la misma y un vehículo. Asimismo, se proporcionan métodos para preparar y usar la composición. En particular, la composición se puede usar en el tratamiento de trastornos gastrointestinales, tales como estreñimiento crónico y síndrome del intestino irritable.
MX2021000312A 2018-07-09 2019-07-08 Composicion farmaceutica que contiene un peptido. MX2021000312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201811025533 2018-07-09
PCT/IB2019/000716 WO2020012243A2 (en) 2018-07-09 2019-07-08 Pharmaceutical composition containing a peptide

Publications (1)

Publication Number Publication Date
MX2021000312A true MX2021000312A (es) 2021-06-08

Family

ID=68165587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000312A MX2021000312A (es) 2018-07-09 2019-07-08 Composicion farmaceutica que contiene un peptido.

Country Status (6)

Country Link
AR (1) AR115724A1 (es)
BR (1) BR112021000201A2 (es)
CL (1) CL2021000022A1 (es)
CO (1) CO2021000158A2 (es)
MX (1) MX2021000312A (es)
WO (1) WO2020012243A2 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033427A1 (en) 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
MX2020005326A (es) 2008-08-15 2022-03-03 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016521249A (ja) 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
EP3180016A4 (en) 2014-08-11 2018-01-03 Sun Pharmaceutical Industries Ltd Linaclotide stable composition
WO2016097030A1 (en) * 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide

Also Published As

Publication number Publication date
AR115724A1 (es) 2021-02-17
BR112021000201A2 (pt) 2021-08-10
WO2020012243A3 (en) 2020-03-05
CO2021000158A2 (es) 2021-01-18
CL2021000022A1 (es) 2021-07-19
WO2020012243A2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MY187047A (en) Selective pyy compounds and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
UA111599C2 (uk) Композиція каспофунгіну
IN2013MU03583A (es)
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
EA201792237A1 (ru) Фармацевтические составы
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MX2021000312A (es) Composicion farmaceutica que contiene un peptido.
PH12017501736A1 (en) Indole derivatives
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2018005345A (es) Composiciones farmaceuticas de dimetil fumarato.
MX2022004014A (es) Composicion liofilizada que contiene 2-((s)-2-acetamido-3-(1h-indo l-3-il)propanamido)-6-diazo-5-oxohexanoato de (s)-isopropilo para administracion intravenosa y su uso.
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
WO2019151966A3 (en) Pharmaceutical tablet compositions of dabigatran